Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.
Journal Article (Journal Article)
Saliva contains factors that inhibit infection with the human immunodeficiency virus type 1 (HIV-1) in vitro. One of these factors was recently identified as secretory leukocyte protease inhibitor (SLPI), a salivary protein which blocked HIV-1 infectivity of monocytes and primary T cells at physiologic concentrations (J Clin Invest 1995; 96: 456). Here, we confirm and extend the original report by demonstrating that SLPI protects primary monocytes and peripheral blood mononuclear cells against infection with HIV-1 Ba-L, IIIB and NL4-3. Thus, SLPI may provide a natural barrier against oral transmission of HIV-1.
Full Text
Duke Authors
Cited Authors
- Shugars, DC; Sauls, DL; Weinberg, JB
Published Date
- May 1997
Published In
Volume / Issue
- 3 Suppl 1 /
Start / End Page
- S70 - S72
PubMed ID
- 9456661
International Standard Serial Number (ISSN)
- 1354-523X
Digital Object Identifier (DOI)
- 10.1111/j.1601-0825.1997.tb00379.x
Language
- eng
Conference Location
- Denmark